Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Snc-80 SCHEMBL7233538 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1MEN1KMT2ACYP3A4 | |
| Snc-80 SCHEMBL3366042 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1MEN1KMT2ACYP3A4 | |
| Snc-80 SCHEMBL12019443 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1MEN1KMT2ACYP3A4 | |
| Snc-80 SCHEMBL1514203 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1MEN1KMT2ACYP3A4 | |
| Snc-80 SCHEMBL724753 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1MEN1KMT2ACYP3A4 | |
| Snc-80 SCHEMBL1514202 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1MEN1KMT2ACYP3A4 | |
| SCHEMBL4586923 | 0.94 | OPRD1 (0.89) | OPRD1OPRM1MEN1KMT2ACYP3A4 | |
| SCHEMBL6935931 | 0.92 | CYP3A4 (0.85) | OPRD1OPRM1MEN1KMT2ACYP3A4 | |
| SCHEMBL6935922 | 0.92 | CYP3A4 (0.85) | OPRD1OPRM1MEN1KMT2ACYP3A4 | |
| SCHEMBL5141891 | 0.90 | OPRD1 (0.82) | OPRD1OPRM1MEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4646477-A2 | METHODS AND COMPOSITIONS FOR DISPLAYING PEPTIDE LIBRARIES | Board of Regents, The University of Texas System (US) | 2025-11-12 | — | — | EP | disclosed |
| WO-2024148130-A2 | METHODS AND COMPOSITIONS FOR DISPLAYING PEPTIDE LIBRARIES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-11 | — | — | WO | disclosed |
| CN-113292559-B | Morphinan derivatives | 日本化学药品株式会社 | 2024-04-02 | — | — | CN | disclosed |
| CN-117122598-A | Use of morphinan derivatives in the treatment of opioid delta receptor agonist-related diseases | 日本化学药品株式会社 | 2023-11-28 | — | — | CN | disclosed |
| CN-116997360-A | Pharmaceutical composition for treating or preventing stress-related disorders | 学校法人东京理科大学 | 2023-11-03 | — | — | CN | disclosed |
| CN-110248658-B | Use of morphinan derivatives in the treatment of opioid delta receptor agonist-related diseases | 日本化学药品株式会社 | 2023-10-13 | — | — | CN | disclosed |
| US-20230141198-A1 | PYRAZOLOMORPHINAN DERIVATIVE | THE KITASATO INSTITUTE (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20220326229-A1 | ASSAY FOR REAL-TIME SIMULTANEOUS RECRUITMENT OF ARRESTIN ISOFORMS TO G PROTEIN-COUPLED RECEPTORS | PURDUE RESEARCH FOUNDATION (US) | 2022-10-13 | — | — | US | disclosed |
| EP-4062972-A1 | PYRAZOLOMORPHINAN DERIVATIVE | The Kitasato Institute (JP) | 2022-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141198-A1 | PYRAZOLOMORPHINAN DERIVATIVE | OPRD1, OPRK1, OPRL1 | OPRD1 1/4885OPRM1 4/4885MEN1 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.